{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06008990",
            "orgStudyIdInfo": {
                "id": "RADY-IIR-19466"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R03DA056797-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R03DA056797-01A1"
                }
            ],
            "organization": {
                "fullName": "Indiana University",
                "class": "OTHER"
            },
            "briefTitle": "Maternal Brain Imaging in Opioid Use Disorder",
            "officialTitle": "Maternal Brain Imaging in Opioid Use Disorder",
            "therapeuticArea": [
                "Women's Health",
                "Other"
            ],
            "study": "maternal-brain-imaging-in-opioid-use-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-18",
            "studyFirstSubmitQcDate": "2023-08-18",
            "studyFirstPostDateStruct": {
                "date": "2023-08-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Rupa Radhakrishnan",
                "investigatorTitle": "Associate Professor of Radiology & Imaging Sciences",
                "investigatorAffiliation": "Indiana University"
            },
            "leadSponsor": {
                "name": "Indiana University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This research study aims to learn more about opioid use disorder (OUD) during pregnancy and how outcomes for pregnant women and their newborns can be improved. During pregnancy, people with OUD are prescribed medication-assisted therapy (MAT). The investigators are interested to know how the medication is broken down by the body during pregnancy and how effective it is. The investigators also want to learn if this medication and OUD have any effect on the different parts of the brain when compared to mothers without OUD."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid Use Disorder",
                "Substance-Related Disorders",
                "Substance Use",
                "Pregnancy Related",
                "Narcotic-Related Disorders",
                "Buprenorphine Dependence"
            ],
            "keywords": [
                "Pregnant with Opioid Use Disorder",
                "Opioid Use Disorder",
                "Subutex",
                "Buprenorphine",
                "Pregnant taking buprenorphine/subutex"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITHOUT_DNA",
                "description": "Biosamples:\n\nDuring the MRI visit blood samples will be collected to estimate steady-state plasma level of buprenorphine using a population pharmacokinetic approach."
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pregnant Mothers with Opioid Use Disorder",
                    "description": "Planned recruitment of 20 mothers with Opioid Use Disorder who are on Buprenorphine at the time of screening.",
                    "interventionNames": [
                        "Drug: Buprenorphine",
                        "Diagnostic Test: Maternal Brain MRI",
                        "Other: Blood Samples",
                        "Behavioral: Questionnaires"
                    ]
                },
                {
                    "label": "Pregnant Mothers",
                    "description": "Planned recruitment of 20 mothers who do not have any history of opioid use disorder.",
                    "interventionNames": [
                        "Diagnostic Test: Maternal Brain MRI",
                        "Behavioral: Questionnaires"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Buprenorphine",
                    "description": "Pregnant mother must be taking Buprenorphine",
                    "armGroupLabels": [
                        "Pregnant Mothers with Opioid Use Disorder"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Maternal Brain MRI",
                    "description": "Maternal Brain MRI obtained between 24-32 week gestation",
                    "armGroupLabels": [
                        "Pregnant Mothers",
                        "Pregnant Mothers with Opioid Use Disorder"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Blood Samples",
                    "description": "During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.",
                    "armGroupLabels": [
                        "Pregnant Mothers with Opioid Use Disorder"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Questionnaires",
                    "description": "Participants will answer questionnaires about their medical history, pregnancy, and substance use.",
                    "armGroupLabels": [
                        "Pregnant Mothers",
                        "Pregnant Mothers with Opioid Use Disorder"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Identify alterations in Default mode network connectivity in women with prenatal opioid use disorder compares to control pregnant women without OUD on maternal brain MRI.",
                    "timeFrame": "During MRI visit between 24-32 weeks gestational age"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Correlate alteration in brain rs-fMRI default mode network connectivity with steady state plasma buprenorphine exposure in pregnant women with OUD",
                    "timeFrame": "During MRI visit between 24-32 weeks gestational age"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Assess differences in brain gray matter volumes in pregnant women with OUD compared to pregnant women without OUD.",
                    "timeFrame": "During MRI visit between 24-32 weeks gestational age"
                },
                {
                    "measure": "Assess differences in brain white matter microstructure on Diffusion Tensor Imaging (DTI) in pregnant women with OUD compared to pregnant women without OUD.",
                    "timeFrame": "During MRI visit between 24-32 weeks gestational age"
                },
                {
                    "measure": "Correlate alterations in brain gray matter volume and DTI metrics with steady state plasma buprenorphine exposure in pregnant women with OUD",
                    "timeFrame": "During MRI visit between 24-32 weeks gestational age"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Pregnant Women with OUD\n\nInclusion Criteria:\n\n* Age: \\>18 years old\n* Any subject that is currently on Buprenorphine at time of screening\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Serious maternal medical illness\n* HIV or AIDs\n* Polysubstance use\n* Score \\>9 on the PHQ-9, and score \\>0 on item 9 which is about suicidality\n* Score of 8 or more on GAD-7\n* Any contraindications for MRI\n* Known or suspected major fetal congenital abnormalities\n\nPregnant Women with no history of OUD\n\nInclusion:\n\n* Age: \\>18 years old\n* Singleton pregnancy\n\nExclusion:\n\n* Serious maternal medical illness\n* HIV or AIDS\n* Score of \\>9 on the PHQ-9, and a score of \\>0 on item 9 which is about suicidality\n* Score of 8 or more on GAD-7\n* Known or suspected major fetal congenital abnormalities\n* Any contraindications for MRI\n* Opioid or polysubstance abuse as identified on urine screening",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "100 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Any woman of the age of 18 or older that is having a single pregnancy, and currently taking buprenorphine for opioid use disorder.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rupa Radhakrishnan, MS, MD",
                    "role": "CONTACT",
                    "phone": "(317) 963-0156",
                    "email": "rradhak@iu.edu"
                },
                {
                    "name": "Karlye Pinto, RN",
                    "role": "CONTACT",
                    "phone": "317-963-8849",
                    "email": "kapinto@iu.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Riley Hospital for Children",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Karlye Pinto, RN",
                            "role": "CONTACT",
                            "phone": "317-963-8849",
                            "email": "kapinto@iu.edu"
                        },
                        {
                            "name": "Brittany Yeley, RN",
                            "role": "CONTACT",
                            "email": "bcyeley@iu.edu"
                        },
                        {
                            "name": "Rupa Radhakrishnan, MS, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                },
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Substance-Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "asFound": "Narcotic-Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002047",
                    "term": "Buprenorphine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "asFound": "Attention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}